Abstract
The traditional gastric balloons have been used for several years to reduce weight in overweight and obese patients, but the need for sedation and upper endoscopy leading to several limitations. The current series is the first study that evaluates the safety and effectiveness of the swallowable gastric (Elipse™) balloon in our population on the national level. Ninety-six patients (mean BMI was 33.6 ± 4.3kg/m2) participated in this study. All patients swallowed one Elipse™ balloon intended to remain in the stomach for 4months, self-empty, and then pass. Each balloon was filled with 550mL of filling fluid. Anti-emetics and anti-spasmodic drugs were prescribed for 2-3days after insertion; proton pump inhibitor was prescribed twice daily 1week before the procedure and continued until the end of residence time (16-20weeks). In the current series, at end of the procedure (after 4months), the overall mean weight loss (WL) was 11.2 ± 5.1kg, mean waist circumference reduction was 10.9 ± 2.1cm, and a mean BMI reduction was 4.9 ± 2.0kg/m2. The percentage of total body weight loss (TBWL%) was 12.1 ± 5.2%. The Elipse™ therapy reported improvements in the metabolic parameters investigated. This swallowable gastric balloon (Elipse™) can be safely and successfully swallowed, filled, imaged, and passed with accepted weight loss and clinical improvement in factors related to the metabolic syndrome.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
